Gameto plans to integrate this meiosis-induction approach with its proprietary ovarian organoid (“ovaroid”) platform to ...

Ovarian cancer standard of care has not advanced in over 30 years, but a new DNA-based immunotherapy could be a gamechanger, showing major survival gains in clinical trials.

Gemogenovatucel-T is a DNA-engineered, triple-function immunotherapy that utilizes a patient's autologous tumor cells as a source for the complete matrix of tumor-related clonal signals. Its mechanism ...

Scientists from University of California, Los Angeles, Harvard University, and elsewhere have developed what they claim is the first comprehensive road map of how the ovarian reserve forms in primates ...

Eli Lilly and Co. has received the U.S. Food and Drug Administration’s breakthrough therapy designation for a drug in development to treat certain ovarian cancer patients. The Indianapolis-based ...

ARTISTRY-7 trial showed no significant survival benefit for nemvaleukin and Keytruda over chemotherapy in platinum-resistant ovarian cancer. Mural Oncology will cease nemvaleukin development for this ...

A microscopy image of the outer region of the rhesus macaque ovary. The developing egg cells are marked by VASA protein (green) and surrounded by supporting granulosa cells marked by FOXL2 (magenta) ...

Researchers at the University of Colorado (UC) Denver, Anschutz Medical Campus, have discovered a novel combination treatment strategy that could offer new hope to ovarian cancer patients who stop ...

On Tuesday, Mural Oncology plc (NASDAQ:MURA) released data from the ARTISTRY-7 phase 3 trial of nemvaleukin alfa in combination with Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) vs.